SCHEMBL5397253

SCHEMBL5397253

CN(Cc1cccc(-c2ccc(C=C3SC(=O)NC3=O)cc2)c1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
KMT2A Q03164 1/20 0.53
PTPN1 P18031 4/20 0.52
HPGD P15428 7/20 0.51
GSK3B P49841 1/20 0.50
PIM1 P11309 4/20 0.48
PIM2 Q9P1W9 4/20 0.48
PIM3 Q86V86 1/20 0.48
AKR1B1 P15121 1/20 0.47
NAT1 P18440 1/20 0.47
IGF1R P08069 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5397249 1.00 MEN1 (0.53) MEN1POLBKMT2APTPN1HPGD
SCHEMBL6185163 0.90 HSD17B2 (0.51) MEN1POLBKMT2APTPN1HPGD
SCHEMBL6185166 0.90 HSD17B2 (0.51) MEN1POLBKMT2APTPN1HPGD
SCHEMBL6186395 0.89 PTPN1 (0.49) MEN1POLBKMT2APTPN1HPGD
SCHEMBL6186392 0.89 PTPN1 (0.49) MEN1POLBKMT2APTPN1HPGD
SCHEMBL6184071 0.89 MEN1 (0.47) MEN1POLBKMT2APTPN1HPGD
SCHEMBL6184070 0.89 MEN1 (0.47) MEN1POLBKMT2APTPN1HPGD
SCHEMBL6182018 0.88 HPGD (0.54) KMT2APTPN1HPGDNAT1
SCHEMBL6182023 0.88 HPGD (0.54) KMT2APTPN1HPGDNAT1
SCHEMBL6187418 0.88 PTPN1 (0.48) MEN1POLBKMT2APTPN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294639-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-11-13 US disclosed
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2007-02-22 US disclosed
US-7122564-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-17 US disclosed
EP-1458697-B1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RES & DEV (FR) 2006-09-06 EP disclosed
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. 2005-06-23 US disclosed
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
EP-1458697-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS Galderma Research & Development, S.N.C. (FR) 2004-09-22 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-07-17 US disclosed
WO-2003055867-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-07-10 WO disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors PPARG, PPARA, PPARD MEN1 4881/4885POLB 1250/4885KMT2A 2763/4885
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD MEN1 4750/4885POLB 1131/4885KMT2A 3011/4885
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD MEN1 4881/4885POLB 1250/4885KMT2A 2763/4885
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD MEN1 4878/4885POLB 1198/4885KMT2A 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.